enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. List of antiviral drugs - Wikipedia

   en.wikipedia.org/wiki/List_of_antiviral_drugs

   Acyclovir (Aciclovir) Herpes Simplex, chickenpox, [2] varicella zoster virus: GSK: guanosine analogue RTI 1981 Adefovir: Hepatitis B [3] Gilead Sciences RTI 2002 , 2003 Amantadine: Influenza: Influenza A virus M2 proton channel antagonist Ampligen: Avian Influenza: Immunomodulatory double-stranded RNA: Amprenavir (Agenerase) HIV Protease ...

3. Valaciclovir - Wikipedia

   en.wikipedia.org/wiki/Valaciclovir

   Valaciclovir, also spelled valacyclovir, is an antiviral medication used to treat outbreaks of herpes simplex or herpes zoster (shingles). [2] It is also used to prevent cytomegalovirus following a kidney transplant in high risk cases. [2]

4. Aciclovir - Wikipedia

   en.wikipedia.org/wiki/Aciclovir

   Aciclovir, also known as acyclovir, [4] is an antiviral medication. [5] It is primarily used for the treatment of herpes simplex virus infections, chickenpox , and shingles . [ 6 ] Other uses include prevention of cytomegalovirus infections following transplant and severe complications of Epstein–Barr virus infection.

5. Surge in walking pneumonia affects these high-risk groups ...

   www.aol.com/news/surge-walking-pneumonia-affects...

   For viral pneumonias, over-the-counter medications can help relieve symptoms. Experts also recommend drinking plenty of fluids, getting lots of rest and keeping the airways open by using a humidifier.

6. CVS, Walgreens and Rite Aid are closing thousands of stores ...

   www.aol.com/finance/why-many-drug-stores-closing...

   CVS, the largest US chain, closed 244 stores between 2018 and 2020. In 2021, it announced plans to close 900 stores by 2024. Walgreens said in 2019 it would close 200 stores and in June announced ...

7. Walgreens: A New Risk Just Emerged for the Stock - AOL

   www.aol.com/finance/walgreens-risk-just-emerged...

   At this point, Walgreens stock is trading at a very inexpensive valuation, with a forward price-to-earnings (P/E) of just over 4.5 times earnings based on this fiscal year's analyst estimates and ...